Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

3.360 -0.930 (-21.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Phathom Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Phathom Pharmaceuticals Provides Regulatory Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Credit Acceptance, and Phathom and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BMO Capital Maintains Outperform Rating for Phathom Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Why Shares of Phathom Pharmaceutical Jumped This Week
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy. 
Via The Motley Fool
Seagate, Boot Barn, Tesla And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion. 
Via Benzinga
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
From Phathom Pharmaceuticals
Via GlobeNewswire
Dow Gains 150 Points After Fed Minutes
U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting. 
Via Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Rises Over 100 Points; Crude Oil Drops Sharply
U.S. stocks extended gains midway through trading, with the Dow Jones gaining around 250 points on Wednesday ahead of the release of minutes from the Fed's meeting. 
Via Benzinga
US Stocks Open Higher Ahead Of Fed Minutes; Dow Rises 100 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Wednesday. 
Via Benzinga
FDA Issues No Action Notice For Phathom Pharma's Investigational Candidate, Shares Plunge
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! 
Via InvestorPlace
Vera Therapeutics, Phathom Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
From Phathom Pharmaceuticals
Via GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
NASDAQ:PHAT Shareholder Alert: Investigation over Possible Securities Laws Violations by Phathom Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 11/15/2022 -- Phathom Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.